Inhibitory effect of the reversal agents V-104, GF120918 and Pluronic L61 on MDR1 Pgp-, MRP1- and MRP2-mediated transport by Evers, R et al.
Simultaneous resistance of tumour cells against a range of cyto-
toxic drugs is a serious problem in cancer chemotherapy. This
phenomenon is called multidrug resistance (MDR). One form of
MDR can be caused by members of the ATP-binding cassette
(ABC) family of transport proteins (Gottesman et al, 1995; Cole
and Deeley, 1998). These are large polytopic membrane proteins
that actively transport drugs out of the cell, resulting in a decreased
intracellular drug concentration. In humans, two ABC transporters
have been identified that can cause resistance in tumour cells:
MDR1 P-glycoprotein (Pgp) (Juliano and Ling, 1976), and the
multidrug resistance protein (MRP1) (Cole et al, 1992). MDR1
Pgp transports drugs in an unmodified form, whereas MRP1 trans-
ports drugs either conjugated to the anionic ligands glutathione
(GSH), glucuronide, or sulphate (Leier et al, 1994; Müller et al,
1994; Jedlitschky et al, 1997), or transports them in an unmodified
form, probably together with GSH (Rappa et al, 1997; Loe et al,
1998).
Another human ABC transporter that might contribute to drug
resistance is the liver canalicular multispecific organic anion trans-
porter (cMOAT or MRP2). Studies with mutant rats (TR–/GY or
EHBR) that lack the MRP2 protein in the canalicular membrane of
the hepatocytes and with cell lines stably transfected with MRP2
cDNA have demonstrated that the substrate specificity of this
transporter is similar to that of MRP1, and suggested that MRP2 is
able to transport several anti-cancer drugs (e.g. Evers et al, 1998;
Masuda et al, 1998; Chen et al, 1999; Cui et al, 1999; Hooijberg et
al, 1999). Besides MRP1 and MRP2, at least four other MRP
homologs have been identified: MRP3, MRP4, MRP5 and MRP6
(Kool et al, 1997; 1999a). MRP3 has been shown to transport
organic anions and confers low-level resistance against etoposide
and tenoposide, and high-level resistance against methotrexate
(Hirohashi et al, 1999; Kool et al, 1999b). Recently, a correlation
was found between the overexpression of MRP4 and resistance
against nucleoside-based antiviral drugs (Schuetz et al, 1999).
The potential involvement of the overproduction of drug pumps
in clinical drug resistance in tumour cells has led to a search for
compounds that can be used to inhibit these transporters in cancer
patients. These so-called reversal agents or modulators should
preferably be: i) Selective for one or more transporters and bind to
these transporters with a high affinity, ii) non-toxic, and iii) stable
in human plasma (Sarkadi and Müller, 1997). Several compounds
have been described that effectively block MDRI Pgp-mediated
drug resistance, some of which are currently being tested in the
clinic (e.g. Fisher and Sikic, 1995; Rowinsky et al, 1998).
Examples of such inhibitors are the non-immunosuppressive
cyclosporin A analogue PSC833 (Twentyman and Bleehen, 1991),
the pipecolinate derivative VX710 (Germann et al, 1997a;
Yanigazawa et al, 1999), the acridone carboxamide derivative
GF120918 (Hyafil et al, 1993), and the (poly)oxypropethylene and
(poly)oxypropylene block copolymers Pluronic L61 and P85
(Venne et al, 1996; Miller et al, 1997; Batrakova et al, 1998).
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Summary The human multidrug transporter MDR1 P-glycoprotein and the multidrug resistance proteins MRP1 and MRP2 transport a range
of cytotoxic drugs, resulting in multidrug resistance in tumour cells. To overcome this form of drug resistance in patients, several inhibitors
(reversal agents) of these transporters have been isolated. Using polarized cell lines stably expressing human MDR1, MRP1 or MRP2 cDNA,
and 2008 ovarian carcinoma cells stably expressing MRP1 cDNA, we have investigated in this study the specificity of the reversal agents
V-104 (a pipecolinate derivative), GF120918 (an acridone carboxamide derivative also known as GG918), and Pluronic L61 (a
(poly)oxypropethylene and (poly)oxypropylene block copolymer). Transport experiments with cytotoxic drugs with polarized cell lines indicate
that all three compounds efficiently inhibit MDR1 Pgp. Furthermore, V-104 partially inhibits daunorubicin transport by MRP1 but not
vinblastine transport by MRP2. V-104 reverses etoposide resistance of 2008/MRP1 cells, whereas GF120918 does not reverse resistance
due to MRP1. V-104 partially inhibits the export of the organic anion dinitrophenyl S-glutathione by MDCKII-MRP1 but not by MDCKII-MRP2
cells. Unexpectedly, export of the organic anion calcein by MDCKII-MRP1 and MDCKII-MRP2 cells is stimulated by Pluronic L61, probably
because it relieves the block on entry of calcein AM into the cell by endogenous MDR1 Pgp. © 2000 Cancer Research Campaign
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doi: 10.1054/ bjoc.2000.1260, available online at http://www.idealibrary.com on Recently, we established two model systems suitable for testing
inhibitors of MDR1 Pgp, MRP1 and MRP2: i) A set of polarized
cell lines stably expressing MDR1, MRP1, or MRP2 cDNA
(Schinkel et al, 1995; Evers et al, 1996; 1998). In these cells
MDR1 Pgp and MRP2 are localized in the apical plasma
membrane, whereas MRP1 is localized in the lateral plasma
membrane. The ability of these cell lines to grow in a monolayer
make them suitable for drug-transport studies and for determining
the specificity and efficiency of inhibitors (Evers et al, 1996; 1998;
Smith et al, 1998); ii) 2008 ovarian carcinoma cells stably
expressing various MRPs (Hooijberg et al, 1999; Kool et al,
1999b).
To further explore the suitability of transfected (polarized) cell
lines for the screening of reversal agents and to investigate the
specificity of previously identified reversals, we describe in this
report the effect of the inhibitors Pluronic L61, V-104 (an analogue
of VX710), and GF120918 on MDR1 Pgp-, MRP1- and MRP2-
mediated transport.
MATERIALS AND METHODS
Materials
[3H]Vinblastine (15 Ci mmol–1), [14C]-1-chloro-2,4-dinitrobenzene
([14C]CDNB; 10 Ci mol–1), and inulin-[14C] carboxylic acid
(5.95 Ci mol–1) were obtained from Amersham Pharmacia Biotech
(Little Chalfont, UK). [3H]Daunorubicin (4 Ci mmol–1) was from
NEN Life Science Products (Boston, MA, USA). Calcein
acetoxymethyl (AM) ester was from Molecular Probes (Leiden,
The Netherlands), Pluronic L61 from Supratek Pharma Inc.
(Laval, Canada), V-104 ((S)-1-[2-Oxo-2-(3,4,5-trimethoxy-
phenyl)acetyl]piperidine-2-carboxylic acid (R and S)-1-(3-phenyl-
propyl)-4-pyridin-3-yl-butyl ester; also called VRT-010367) from
Vertex Pharmaceuticals Inc. (Cambridge, MA, USA), and GF
120918 from GlaxoWellcome (Greenford, UK). Other chemicals
and drugs were from Sigma Chemical Co. (St Louis, MO, USA).
Cell lines
Polarized canine (MDCKII) or porcine (LLC-PK1) kidney-cell
lines stably expressing MDR1, MRP1, or MRP2 (cMOAT) have
been described before (Schinkel et al, 1995; Evers et al, 1997;
1998; Bakos et al, 1998). MDCKII-derived cell lines were cultured
in DMEM with 10% fetal calf serum, LLC-PK1-derived cell lines
in Medium 199 with 10% fetal calf serum. 2008/MRP1 cells have
been described before (Hooijberg et al, 1999), and were cultured in
RPMI 1640 with 10% fetal calf serum.
Transport assays
[3H]vinblastine and [3H]daunorubicin transport assays were
carried out essentially as described (Evers et al, 1996). Cells were
seeded on microporous polycarbonate filters (3 mm pore size,
24.5 mm diameter, Transwell™ 3414; Costar Corp., Cambridge,
MA, USA) and cultured for 3 days with a daily medium replace-
ment. The experiment was started (t = 0) by replacing the medium
at either the apical or the basal side of the cell layer with 2 ml of
complete medium containing 2 mM of drug (at 0.25 mCi ml–1),
[14C]-labelled inulin (0.025m Ci ml–1), and the amount of inhibitor
indicated. The cells were incubated at 37°C, 5% CO2. 50 ml
aliquots were taken from each compartment at various time-points.
Radioactivity was measured as the fraction of radioactivity added
at the beginning of the experiment. The paracellular flux was
monitored by the appearance of inulin [14C]carboxylic acid in the
opposite compartment and was typically below 1.5% per h.
Inhibition of transport by inhibitors was calculated by dividing the
net flux of drug in the control experiment (at t = 4 h) by the net
flux determined in the presence of inhibitor. Export of [14C]DNP-
GS was determined by incubating cells with 2 mM of [14C]CDNB
(15 nCi ml–1) at room temperature as described previously (Evers
et al, 1996; 1998), with the modification that the experiments were
performed in Hanks Balanced Salt Solution (containing 1.3 mM
CaCl2). If inhibitors were used in the experiment, cells were first
incubated with HBSS containing inhibitor for 10 min before
adding the substrate. Export of calcein was determined by
incubating monolayers in HBSS containing calcein AM (1 mM) at
room temperature. Samples (200 ml) were taken at the time-points
indicated. 800 ml HBSS was added and fluorescence was deter-
mined in a fluorimeter (Perkin-Elmer). The amount of calcein
exported was calculated using a calibration curve made with free
calcein.
All transport experiments were performed in duplicate and
repeated at least twice.
Cytotoxicity assays
The drug sensitivity of cells was determined as described (Kool et
al, 1999b) in growth inhibition assays with continuous exposure to
drug.
RESULTS
Inhibition of drug transport by Pluronic L61
To examine whether Pluronic L61 inhibits transport mediated by
MDR1 Pgp, vectorial transport of vinblastine was measured in
LLC-MDR1 cells in the presence of various Pluronic L61 concen-
trations. Figure 1 shows that transport was blocked by this
compound; total inhibition of vinblastine transport was already
obtained at a Pluronic L61 concentration of 0.04% (w/v). No effect
on the paracellular [14C]inulin flux was observed at concentrations
up to 0.1% (w/v) Pluronic L61 (results not shown). To investigate
whether Pluronic L61 could inhibit vinblastine transport by
MRP2, we transfected MDCKII cells (Evers et al, 1998), as
MRP2-mediated transport was very low in transfected LLC-PK1
cells (RE and PB, unpublished data). In these experiments a low
concentration of the Pgp inhibitor PSC833 (0.1 mM) was present
to inhibit the endogenous Pgp in these cells. This concentration of
PSC833 only partially inhibits MDR1 Pgp in MDCKII-MDR1
cells and has no effect on vinblastine transport by MDCKII-MRP2
cells. At the highest concentration Pluronic L61 (0.1% (w/v))
tested, some inhibition (1.5-fold) of net vinblastine transport by
MDCKII-MRP2 cells was observed, whereas transport mediated
by MDR1 Pgp was completely blocked under these conditions
(Figure 2). At lower concentration of Pluronic L61 (0.04% (w/v)),
transport by MRP2 was not affected at all, whereas transport by
MDR1 Pgp was totally blocked (data not shown).
The effect of Pluronic L61 on MRP1 is summarized in Table 1.
In polarized cells MRP1 routes to the basolateral membrane (Evers
et al, 1996) and not to the apical membrane, like Pgp and MRP2.
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through kidney-cell monolayers (Evers et al, 1996), and we there-
fore studied transport of dinitrophenol S-glutathione ([14C]DNP-
GS) instead (Oude Elferink et al, 1993; Evers et al, 1996; 1998).
DNP-GS does not enter the cells, but cells do take up the precursor
[14C]CDNB, which is converted intracellularly into DNP-GS by
glutathione S-transferases (GSTs). Table 1 shows that Pluronic
L61 has a small inhibitory effect on the basolateral [14C]DNP-GS
export by MDCKII-MRP1 cells, but also on apical export by
MDCKII-MRP2 cells. As the total amount of DNP-GS retrieved in
medium and cells was somewhat lower in the presence of Pluronic
L61 in all cell lines (Table 1), it is probable that Pluronic L-61 had
some inhibitory effect on the formation of DNP-GS rather than
directly on MRP.
Calcein acetoxy-methyl ester (calcein AM) is a lipophilic
compound that enters the cell by passive diffusion over the plasma
membrane. Cleavage of the ester bonds by intracellular esterases
converts calcein AM into the highly fluorescent organic anion
calcein. Calcein AM itself is efficiently transported by MDR1 Pgp
(Homolya et al, 1996), and MRP1 transports both calcein AM and
calcein (Feller et al, 1995; Holló et al, 1996). As transport of
fluorescent substrates can be conveniently measured using a
fluorimeter, we investigated whether calcein could be used as a
substrate to study the function of MRP1 and MRP2 in MDCKII
cells. Cells were incubated in the presence of calcein AM and the
amount of calcein appearing in the medium was determined.
Figure 3A shows that in MDCKII wild-type cells calcein export to
the apical and basolateral side was similar. Hardly any calcein
export was detected in MDCKII-MDR1 cells (Figure 3B), some
increased (2-fold) basolateral export was observed in MDCKII-
MRP1 cells (Figure 3C), and a 3-fold increased apical export was
measured in MDCKII-MRP2 cells (Figure 3D). Unexpectedly, in
the presence of Pluronic L-61 calcein export to the basolateral side
by the MDCKII-MRP1 cells was increased 2-fold (t = 2 h), and
export to the apical side by the MDCKII-MRP2 cells was
increased 4-fold. Similar data were obtained in the presence of
higher Pluronic L61 concentrations (data not shown). An obvious
explanation for this paradoxical stimulation is that Pluronic L61
inhibits the endogenous MDR1 Pgp present in MDCKII cells and
that this Pgp limits the entry of calcein AM in the absence of
Pluronic L61. To test this hypothesis, calcein transport was
measured in the presence of PSC833 (0.1 mM). This concentration
of PSC833 had some stimulatory effect on export by MDCKII-
MRP2 cells, but no effect on export by MDCKII-MRP1 cells
(Figure 3C and 3D).
Inhibition of drug transport by V-104
VX710 is a potent inhibitor of MDR1 Pgp in several drug-selected
cell lines that overexpress MDR1 (Germann et al, 1997a). In addi-
tion, VX710 partially reverses the MDR phenotype of MRP1 over-
expressing cells (Germann et al, 1997b; Yanagisawa et al, 1999).
An analogue of VX710 has been developed called V-104. At
15 mM, V-104 effectively inhibited daunorubicin and vinblastine
transport by MDCKII-MDR1 cells (Figures 4B and 5B). Hardly
any inhibition of MDR1 was observed at lower concentrations of
V-104 (5 mM) (data not shown). V-104 at 15 mM had a modest
inhibitory effect on MRP1. The low daunorubicin transport by
MDCKII-MRP1 shown in Figure 4C was somewhat decreased by
the drug. DNP-GS export (Table 1) was decreased as well. Note
that the experiments with MDCKII-MRP1 cells in Table 1 show
that V-104 decreases basolateral DNP-GS transport by nearly
30%, whereas endogenous DNP-GS goes up 2-fold. As substrate
(DNP-GS) production could be limiting to some extent in these
cells, the 30% inhibition is a minimal value. In contrast, vinblas-
tine transport by MDCKII-MRP2 cells was not affected by
V-104 (Figure 5C). Table 1 shows that export of DNP-GS from
MDCKII-MRP2 cells was not significantly affected by V-104
either.
Inhibition of drug transport by GF120918
GF120918 is an efficient inhibitor of MDR1 Pgp (Hyafil et al,
1993; Wallstab et al, 1999). Figures 4B and 5B show that
GF120918 completely inhibited daunorubicin and vinblastine
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Figure 1 Effect of Pluronic L61 on vinblastine transport by LLC-PK1 and
LLC-MDR1 cells. (Left graphs) LLC-PK1 wild-type cells. At t = 0
[3H]vinblastine (2 mM) was applied either to the apical or basolateral
compartment, and the amount of radioactivity appearing in the opposite
compartment was determined. Transport is presented as the fraction of total
radioactivity added at the beginning of the experiment, appearing in the
opposite compartment. (Right graphs) Same as left graphs but LLC-MDR1
cells were tested. Transport was tested in the absence of Pluronic L61 (A), or
in the presence of 0.008% (w/v) (B), 0.016% (w/v) (C), or 0.04% (w/v)
Pluronic L61 (D). Squares: translocation from basolateral to apical. Circles:
translocation from apical to basolateral. Experiments were performed in
duplicate. Variation between measurements was between the size of the
symbolstransport by MDCKII-MDR1 cells, whereas transport of daunoru-
bicin by MDCKII-MRP1 cells (Figure 4C) and vinblastine trans-
port by MDCKII-MRP2 cells (Figure 5C) was not affected. Table
1 shows that export of DNP-GS by MDCKII-MRP1 and MDCKII-
MRP2 cells was not inhibited by GF120918 either.
Reversal of drug resistance by V-104 and GF120918
To test whether the reversal agents GF120918 and V-104 were
able to reverse the drug resistance of 2008/MRP1 cells, we
performed growth inhibition assays with continuous drug expo-
sure with or without inhibitor. The maximum concentrations of
the inhibitors that were not cytotoxic during a continuous expo-
sure were 10 mM and 5 mM for GF120918 and V-104, respec-
tively. We examined reversal of resistance to etoposide, as
2008/MRP1 cells are highly resistant (20-fold) against this drug.
V-104 reversed etoposide resistance of the 2008/MRP1 cells, but
reversal was not complete, even at 5 mM (Table 2). Sensitivity of
mock-transfected cells to etoposide also increased somewhat in
the presence of V-104, presumably because of the inhibition of
endogenous transporters. Inhibition of endogenous Pgp may also
explain the effect found for GF120918 on etoposide resistance,
as this effect did not clearly increase with GF120918 concentra-
tion.
DISCUSSION
Specific inhibitors of drug transporters are potentially useful tools
for the dissection of complex drug-resistance phenotypes and,
eventually, for the treatment of patients with drug-resistant cancer.
We have tested the specificity of three novel compounds, Pluronic
L61, V-104 and GF120918, on three drug transporters, MDR1
Pgp, MRP1 and MRP2, in intact (transfected) cells. The trans-
fected LLC-MDR1 cell line used in this study was selected with
vincristine, whereas the MDCKII-derived cell lines were selected
with geneticin (G-418). We therefore cannot formally exclude that
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Figure 2 Effect of Pluronic L61 on vinblastine transport through polarized MDCKII cell monolayers. Transport of [3H]vinblastine was performed as in Figure 1,
but with PSC833 (0.1 mM) present in the apical and basal compartment during all experiments. (A) Transport in MDCKII, MDCKII-MDR1 and MDCKII-MRP2
cells, respectively. (B) Same as A, but transport was determined in the presence of Pluronic L61 (0.1% (w/v)). Squares: translocation from basolateral to apical.
Circles: translocation from apical to basolateral
Table 1 Effect of various inhibitors on DNP-GS transport by MDCKII cell monolayers
Cell line MDCKII MDCKII-MRP1 MDCKII-MRP2
inhibitor Apical Basal Intracellular Total Apical Basal Intracellular Total Apical Basal Intracellular Total
Control 490 ± 19 855 ± 6 1456 ± 10 2801 185 ± 5 2113 ± 61 136 ± 0 2434 1670 ± 43 506 ± 4 315 ± 8 2491
Pluronic L61 (0.1%) 393 ± 17 1167 ± 10 861 ± 0 2401 147 ± 6 1818 ± 12 131 ± 11 2096 1396 ± 13 450 ± 7 239 ± 23 2085
V-104 (15 mM) 737 ± 39 767 ± 12 806 ± 2 2301 196 ± 18 1497 ± 26 290 ± 6 1983 1765 ± 13 440 ± 3 186 ± 5 2391
GF120918 (5 mM) 616 ± 17 1200 ± 41 796 ± 27 2612 218 ± 0 2246 ± 29 166 ± 1 2630 1728 ± 27 570 ± 27 225 ± 17 2523
Cells growing in a monolayer were preincubated in the presence of the inhibitors indicated for 10 min. At t = 0 [14C]CDNB (final concentration 2 mM; 15 nCi ml–1)
was added to both the apical and basal compartment. Samples were taken at t = 1, 3, 6, 12, and 20 min and extracted with ethyl acetate. The experiments were
performed in duplicate and the variation between the measurements is indicated. Values presented represent the total amount of [14C]DNP-GS (in pmoles)
formed after 20 min.these lines have developed some unknown mechanisms of drug
resistance. We consider this, however, an unlikely possibility as
untransfected cells never formed colonies after selection with
vincristine or G-418, respectively. All three compounds
completely inhibit MDR1 Pgp-mediated transport of vinblastine
and daunorubicin at non-cytotoxic concentrations in our assays.
GF120918 and V-104 have no effect on transport by MRP2. V-104
is a weak inhibitor of MRP1, but we only observed clear inhibition
at drug concentrations close to cytotoxic levels. It is therefore
unlikely that this drug will be useful for inhibiting MRP1 in
human cancer. A high concentration (0.1%) of Pluronic L61
partially inhibited vinblastine transport by MRP2 (Figure 2), but
had only a small effect on DNP-GS transport by MRP2. Our data
also show that the interpretation of inhibitor studies can be compli-
cated by the presence in the cells of other endogenous transporters
with a high affinity for the inhibitor, the transport substrate used,
or both. In the screening for inhibitors of MRP1 and MRP2, it is
obviously important to use both organic anions and cytotoxic
drugs as substrates, as inhibitors may have a differential effect on
the transport of different classes of drugs.
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Figure 3 Export of calcein by MDCKII cell monolayers. (A, left graph) MDCKII wild-type cells. At t = 0 calcein AM (1 mM) was added to both the apical and
basolateral medium, and the amount of calcein appearing in the medium was measured using a fluorimeter. Samples were taken at t = 1 and t = 2 h. (Middle
and right graph) Same as left graph, but the assay was performed in the presence of PSC833 (0.1 mM) or Pluronic L61 (0.04%), respectively. (B–D) Same as
(A), but MDCKII-MDR1, MDCKII-MRP1 and MDCKII-MRP2 cells were tested, respectively. Squares: export to apical compartment. Circles: export to basolateral
compartmentPrevious work has shown that P85, an analog of Pluronic L61,
inhibits an apically localized drug transporter in CaCo-2 cells,
most likely MDR1 Pgp (Batrakova et al, 1998). With transfected
cell lines we show here that MDR1 Pgp is indeed inhibited by this
class of compounds. The mechanism of action of the copolymer
Pluronic L61 is not clear. It is not known whether it is a substrate
for MDR1 Pgp (and therefore acts as a competitive inhibitor) or
blocks MDR1 Pgp by another mechanism. Amphiphilic block
copolymers have a low critical micelle concentration (cmc); the
cmc for Pluronic L61 is 0.02% (w/v) (Batrakova et al, 1996). As
we see a major inhibition of MDR1 Pgp below 0.02% (w/v)
(Figure 1), we conclude that the monomeric form of Pluronic L61
is the effective species in inhibiting transport, in agreement with
earlier suggestions by Miller et al (1997) and Batrakova et al
(1998) for Pluronic analogues, and Nerurkar et al (1997) for other
neutral surfactants. Our results show that the inhibitory effect of
Pluronic L61 on Pgp is highly specific. We clearly show that
Pluronic L61 does not increase the rate of passive diffusion of drug
through the monolayer and that it has no clear effect on MRP1 or
MRP2. It is therefore likely that Pluronic L61 directly binds to
Pgp, like other inhibitors, but we have not verified this in a simple
vesicular transport system, e.g. by vanadate-mediated nucleotide
trapping (Szabo et al, 1998). Very recently, Miller et al (1999)
suggested that Pluronic L61 and P85 do inhibit MRP1 in a human
pancreatic adenocarcinoma cell line. These authors studied the
accumulation of fluorescein and observed some increased intra-
cellular accumulation in the presence of various Pluronic
analogues. The discrepancy with our data may be explained by the
presence of other organic anion transporters than MRP1 in pancre-
atic adenocarcinoma cells; one of these might be sensitive towards
Pluronic analogues. Our data clearly indicate that in MDCKII
cells, neither MRP1 nor MRP2 are inhibited significantly by
Pluronic L61. Firstly, DNP-GS export by MRP1 or MRP2
was only slightly impaired (Table 1) and, secondly, vinblastine
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Figure 4 Effect of V-104 and GF120918 on daunorubicin transport through polarized MDCKII cell monolayers. Transport was measured as described in Figure
2, but with [3H]daunorubicin as substrate. (A, left graph) MDCKII cells. Transport in the presence of PSC833 (0.1 mM) alone. (Middle and right graph) Same
as left graph, but in addition to PSC833, V-104 (15 mM) and GF120918 (1 mM) were added at t = 0. (B,C) Same as A, but MDCKII-MDR1 and MDCKII-MRP1
cells were tested, respectively. Squares: translocation from basolateral to apical. Circles: translocation from apical to basolateral.372 R Evers et al
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Figure 5 Effect of V-104 and GF120918 on vinblastine transport through polarized MDCKII monolayers. Transport was measured as in Figure 4, but with
[3H]vinblastine as substrate.
Table 2 Growth inhibition of 2008/MRP1 and mock transfected 2008/pCMV-neo cells by
etoposide
2008/pCMV-neo 2008/MRP1
IC50 (nmol) IC50 (nmol)
Etoposide 0.42 ± 0.06 (1.0) 8.84 ± 1.44 (20)
Etoposide 0.36 ± 0.00 (0.9) 9.77 ± 5.24 (27)
+ 1.0 mM GF120918
Etoposide 0.31 ± 0.03 (0.7) 4.27 ± 0.80 (14)
+ 2.5 mM GF120918
Etoposide 0.31 ± 0.01 (0.7) 6.98 ± 1.86 (23)
+ 5.0 mM GF120918
Etoposide 0.34 ± 0.02 (0.8) 5.00 ± 2.17 (15)
+ 1.0 mM V-104
Etoposide 0.23 ± 0.00 (0.5) 2.95 ± 0.87 (13)
+ 2.5 mM V-104
Etoposide 0.30 ± 0.11 (0.7) 1.46 ± 0.17 (5)
+ 5.0 mM V-104
IC50s are means of an experiment performed in triplicate. Numbers in parentheses represent
resistance factors (relative to 2008/pCMV-neo incubated with etoposide alone for 2008/pCMV-neo
cells; relative to the identically treated 2008/pCMV-neo cells for 2008/MRP1 cells).transport by MRP2 was only weakly affected at the highest
concentration of Pluronic L61 tested (Figure 2). We observed stim-
ulation of calcein export by MRP1 and MRP2 in the presence of
Pluronic L61 (Figure 3), probably caused by the efficient inhibi-
tion of canine Pgp by this compound. As PSC833 could only
partially mimic this effect, PSC833 cannot block calcein AM
transport by Pgp completely, whereas Pluronic L61 can, or there is
another endogenous transporter of calcein AM inhibited by
Pluronic L61 but not by PSC833.
It is remarkable that many of the reversal agents that efficiently
block MDR1 Pgp, like PSC833, GF120918 and Pluronic L61,
have little or no effect on MRP1 and MRP2 (e.g Böhme et al,
1993; Wallstab et al, 1999). It has been shown that both GF120918
and PSC833 are competitive inhibitors that probably bind with
high affinity to the substrate binding site(s) of MDR1 Pgp (Smith
et al, 1998; Wallstab et al, 1999). Obviously the drug binding sites
of MDR1 Pgp have a higher affinity for hydrophobic inhibitors
than the drug binding sites of MRPs. This could be due to a differ-
ence in transport mechanisms. Whereas MDR1 Pgp does not
require any co-factor for the transport of hydrophobic drugs, trans-
port by MRP1 and MRP2 of these drugs is associated with the
export of reduced glutathione (Rappa et al, 1997; Loe et al, 1998;
Evers et al, 2000). The compounds that we used here are all rela-
tively hydrophobic and not negatively charged. They may there-
fore require GSH for binding to MRPs, and this may result in a
relatively low affinity for the transporter.
Most high-affinity substrates for MRP1 and MRP2 found
thus far are organic anions with a substantial hydrophobic moiety
and one, but preferably two, negative charge(s). Examples are
leukotriene C4, S-decylglutathione and the leukotriene D4 antago-
nist MK571 (Loe et al, 1996; Keppler et al, 1998). These substrates
do not readily enter cells and they therefore do not provide obvious
lead compounds for drug development. As it seems unlikely that
more membrane-permeable compounds can be found with high
affinity for MRP, good inhibitors will have to be made as prodrugs
in which the charged moiety is shielded and can be converted into
active drug in the cell, like CDNB or calcein AM.
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